Indium 111-radiolabelled anti-CD66 ( DrugBank: Indium )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
28全身性アミロイドーシス1

28. 全身性アミロイドーシス


臨床試験数 : 267 薬物数 : 241 - (DrugBank : 77) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 180
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2015-002231-18-GB
(EUCTR)
01/12/201523/09/2015A Phase I/IIa (early phase) Study of Targeted Radiotherapy alone for Stem Cell Transplant Conditioning in Systemic AL AmyloidosisA Phase I/IIa Study of Targeted Radiotherapy alone for Stem Cell Transplant Conditioning in Systemic AL Amyloidosis - Targeted Radiotherapy for AL-Amyloidosis –‘TRALA’ AL-Amyloidosis
MedDRA version: 18.0;Level: LLT;Classification code 10024460;Term: Light chain disease myeloma associated;System Organ Class: 100000004864;Therapeutic area: Diseases [C] - Cancer [C04]
Product Name: CHX-A-DTPA-Anti-CD66
INN or Proposed INN: CHX A-DTPA anti-CD66 antibody
Product Name: Indium­ 111 ­labelled Anti­-CD66
INN or Proposed INN: Indium 111-radiolabelled anti-CD66
Product Name: yttrium-90 radiolabelled anti-CD66 antibody
INN or Proposed INN: Yttrium­90 radiolabelled anti­CD66
University Southampton Hospital NHS Foundation TrustNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
18Phase 1/2United Kingdom